Abstract
Background: Platinum compounds like cisplatin, carboplatin used as anticancer drugs are known to cause nephrotoxicity. There is a need of drugs to prevent the drug induced nephrotoxicity. This experimental study was done to assess the nephroprotective role of rosuvastatin in carboplatin induced nephrotoxicity models and to compare it with melatonin. Methodology: A total of 36 albino rats were randomly divided into 6 groups (n=6). Group I was control group. In Groups II to VI nephrotoxicity was induced by intraperitoneal administration of a single dose of Carboplatin 128mg/kg on day 5. In Group II, no drug was administered. In group III and IV melatonin 5mg/kg and 10mg/kg was administered orally once a day for 10 days. In group V and VI, rosuvastatin 10mg/kg and 20mg/kg was administered orally once a day for 10 days. Blood was collected on day 0 for the baseline values and at an interval of 7 and 11 days for biochemical and antioxidant estimation. Kidneys were dissected at the end of study, weighed and renal tissue was subjected to histopathological analysis. Results: There was a significant decrease in urea, creatinine and uric acid in all the treatment groups. Also a significant decrease (p<0.05) was seen in MDA levels in treatment groups as compared to the negative control. A non-significant decrease was observed in IL-18 levels in the treatment groups. Also, histopathology of kidney tissues showed that in treatment groups, there were less changes in interstitium and vessels. Conclusion: Melatonin and rosuvastatin has shown a nephroprotective effect in carboplatin induced nephrotoxicity in terms of improved renal function tests, reduced IL-18 showing anti-inflammatory action, antioxidant action by decreasing MDA and increasing GSH and by histopathological studies of kidney tissue
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
